Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apremilast in Moderate to Severe Genital Psoriasis
NCT03777436Phase 3Completed
- Sponsor
- Amgen
- Start
- Feb 2019
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 3 trial of apremilast in genital psoriasis, sponsored by Amgen. Started Feb 2019; status: completed.
02
Drugs
apremilast
03
Conditions
genital psoriasis
Beyond the preview
Go deeper on NCT03777436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03777436.